Allergy Therapeutics Results Video & investor meeting details
Allergy Thereapeutics plc (LON:AGY) this morning released their Interim Results for the 6 months ended 31st December 2017. A short video is available below, with further explainer videos available on their company wall.
They reported a 4.4% increase in revenues, and this was against a backdrop of an unusually weak market: the pollen season was abnormally weak this year, leading to less demand for remedies & vaccinations. Their products Venomil and Acarovac Plus performed very well, and there have been a number of developments in AGY’s clinical trial pipeline.
Allergy Thereapeutics increased their R&D expenditure to £5.9m from £3.8m in the previous half. This was due to investment in their grass and Birch vaccine trials ( Grass MATA MPL Phase II and PQ Birch Phase III trials.
UK-WIDE MEETING DETAILS
For professional investors
We are organising UK wide investor meetings with Allergy over the coming year, visiting London, Birmingham, Bristol, Manchester, Leeds, Edinburgh and Glasgow. The meetings are strictly for professional investors, and please contact us if you would like to meet them. We will be releasing dates shortly.